ODG Formulary Changes Planned for March 29

Posted on by myMatrixx
MyMatrixx by Evernorth PharmaWatch Clinical Updates

Effective March 29, ODG is updating Appendix A (its drug formulary). The planned changes will affect opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and sedative hypnotics.

Prolate, an opioid combination containing oxycodone and acetaminophen, will be added as an N drug. Percocet (and its generics), a different combination of the same two drugs, will remain a Y drug. The subtle difference between Prolate and Percocet is that Percocet contains 325 mg of acetaminophen per unit, whereas Prolate contains 300 mg of acetaminophen per unit.

Two different NSAIDs – fenoprofen and ketoprofen – will be changing from their current Y drug status to become N drugs. This will be the case for both the immediate-release and extended-release formulations of ketoprofen.

Trazodone, listed on Appendix A as a sedative hypnotic, will change from its current status as an N drug to become a Y drug.

About ODG

ODG by MCG offers highly configurable, industry-specific medical treatment and return-to-work solutions which are used for managing workers’ compensation, disability, and auto liability claim outcomes with evidence-based, data-driven decision support. They publish the ODG Drug Formulary, known as Appendix A, used by claims and case managers, health-care providers, employers, insurance carriers, third-party administrators, managed care organizations and more.

MyMatrixx maintains ODG-based formularies and will continue to update them in accordance with the planned changes. For any questions, please reach out to your MyMatrixx account team contact.